Impax Laboratories, Inc.

Global Pharmaceuticals Awards Grant to Myasthenia Gravis Alliance [Press Release]
Business Wire | 11 hours 13 minutes ago
Global Pharmaceuticals, the generic products division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced their cooperation in awarding a modest grant to Myasthenia Gravis Alliance, also known as Myasthenia Gravis Foundation of Greater New York, Inc., a 501(3)(c) non profit membership corporation, incorporated in the State of New York. A portion of the grant will fund The Alliance Fellowship for Myasthenia Gravis Research, at the University of California, Davis, under the direction of...

Impax Laboratories Drives Stronger Performance with IBM Business Analytics [Press Release]
PRNewswire | 4 days 5 hours 43 minutes ago
ARMONK, N.Y., Nov. 20 /PRNewswire-FirstCall/ -- IBM

Impax Laboratories Continues Trend of Solid Growth in Revenue, Profit and Earnings for the Third Quarter 2009 [Press Release]
Business Wire | 21 days 13 hours 13 minutes ago
Impax Laboratories, Inc. (NASDAQ: IPXL) today reported strong growth in revenue, net income and earnings per diluted share in the third quarter 2009. Net income increased to $6.7 million, up $17.2 million compared to a net loss of $10.5 million in the prior year period. Net Income per diluted share increased to $0.11, up $0.29 per share, compared to a loss of $0.18 per diluted share in the prior year period.

Impax Laboratories Confirms Patent Challenge Relating to TRICOR 48mg and 145mg Tablets [Press Release]
Business Wire | 25 days 10 hours 58 minutes ago
Impax Laboratories, Inc. (NASDAQ:IPXL) today confirms that it has initiated a challenge of the patents listed by Abbott Laboratories in connection with its TRICOR® (fenofibrate) tablets, 48 mg and 145 mg.

Impax Pharmaceuticals Initiates Second Phase III Trial of IPX066 in Parkinson s Disease [Press Release]
Business Wire | 29 days 12 hours 34 minutes ago
Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ:IPXL), today announced that it has initiated a multinational Phase III trial of its late-stage drug candidate IPX066 in advanced Parkinson’s disease (PD) patients. IPX066 is an investigational extended release carbidopa-levodopa product intended to rapidly achieve and then sustain effective blood concentrations of levodopa, potentially improving PD clinical symptom management. This is the second of two Phas...

Impax Laboratories to Present at the Credit Suisse 18th Annual Healthcare Conference [Press Release]
Business Wire | 14 days 4 hours 29 minutes ago
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Credit Suisse 18th Annual Healthcare Conference on Friday, November 13th, at 10:00 a.m. Mountain Standard time. The conference will be held at the Arizona Biltmore Hotel located in Phoenix, AZ.

Impax Laboratories to Host Third Quarter 2009 Earnings Conference Call and Webcast on November 3 [Press Release]
Business Wire | 42 days 5 hours 8 minutes ago
Impax Laboratories, Inc. (NASDAQ:IPXL) announced today that its third quarter 2009 earnings will be released before the market opens on Tuesday, November 3, 2009 and will be available on Impax’s Web site at www.impaxlabs.com. The Company will host an earnings conference call and live webcast with financial analysts at 11:00 a.m., Eastern time.

Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinson's Disease [Press Release]
PRNewswire | 96 days 12 hours 40 minutes ago
...marketplace, today announced that Impax Pharmaceuticals, the brand division of Impax Laboratories, Inc., Hayward, CA, has selected...success as a company." Impax Laboratories, Inc. is a technology based specialty...

Research and Markets: Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry - Now Available [Press Release]
Business Wire | 4 days 14 hours 19 minutes ago
Research and Markets (http://www.researchandmarkets.com/research/3e1fb3/analyzing_the_gene) has announced the addition of the "Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry" report to their offering.

SHIRE PLC - 3rd Quarter Results [Press Release]
PRNewswire | 25 days 8 hours 43 minutes ago
Shire continues to deliver excellent growth from core products